<p>Coya Therapeutics, Inc.（纳斯达克代码：COYA - 获取免费报告）目前被五家评级公司一致评为 “买入”，MarketBeat Ratings 报告称。五位分析师对该股票给予了买入推荐。在过去一年中，更新了对该股票覆盖的经纪商的平均十二个月目标价为 16.20 美元。</p>
<p>获取 <strong>Coya Therapeutics</strong> 的提醒：</p>
<ul>
<li>你在做节日购物吗？这些股票可能是很好的礼物</li>
</ul>
<p>一些经纪公司最近对 COYA 发表了看法。Lake Street Capital 于 7 月 9 日星期三在一份研究报告中开始覆盖 Coya Therapeutics 的股票。他们给予了 “买入” 评级，并设定了 16.00 美元的目标价。BTIG Research 在周二重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 15.00 美元。Chardan Capital 在 9 月 17 日星期三重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 14.00 美元。HC Wainwright 在 8 月 25 日星期一重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 18.00 美元。最后，D. Boral Capital 在周一重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 18.00 美元。</p>
<p><strong>阅读我们关于 COYA 的最新研究报告</strong></p>
<h2>Coya Therapeutics 股票上涨 1.0%</h2>
<ul>
<li>这些生物技术公司针对多种神经退行性疾病</li>
</ul>
<p>在周二的午盘交易中，纳斯达克：COYA 上涨了 0.06 美元，达到了 5.72 美元。该公司交易了 1,857 股，相比其平均交易量 77,597 股。Coya Therapeutics 的 12 个月低点为 4.65 美元，12 个月高点为 10.24 美元。该公司的 50 日移动平均为 6.13 美元，200 日移动平均为 5.98 美元。该股票的市值为 9,558 万美元，市盈率为-4.61，贝塔值为 0.26。</p>
<p>Coya Therapeutics（纳斯达克代码：COYA - 获取免费报告）最近于 8 月 12 日星期二发布了其财报。该公司报告的每股收益（EPS）为-0.36 美元，低于市场共识预期的-0.22 美元，差距为-0.14 美元。该公司本季度的收入为 16 万美元，而市场共识预期为 78 万美元。平均而言，股票研究分析师预计 Coya Therapeutics 本财年的每股收益将为-1.15 美元。</p>
<h2>对 Coya Therapeutics 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对 COYA 的持仓进行了调整。Dauntless Investment Group LLC 在第一季度购买了 Coya Therapeutics 的新头寸，价值 1,083,000 美元。CM Management LLC 在第一季度将其在 Coya Therapeutics 的持仓增加了 25.0%。CM Management LLC 现在拥有该公司 200,000 股股票，价值 1,294,000 美元，此前在此期间又购买了 40,000 股。西北互助财富管理公司在第二季度收购了 Coya Therapeutics 的新头寸，价值约 119,000 美元。Jane Street Group LLC 在第一季度将其在 Coya Therapeutics 的股份提高了 101.7%。Jane Street Group LLC 现在拥有该公司 26,137 股股票，价值 169,000 美元，此前在上个季度又购买了 13,176 股。最后，Charles Schwab Investment Management Inc. 在第一季度收购了 Coya Therapeutics 的新头寸，价值约 65,000 美元。39.75% 的股票由机构投资者持有。</p>
<h2>Coya Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Coya Therapeutics, Inc. 是一家临床阶段的生物技术公司，专注于开发专有药物产品，以调节调节性 T 细胞（Tregs）的功能。该公司的产品候选管道基于治疗性模式，如增强 Tregs 的生物制剂、Treg 衍生外泌体和自体 Treg 细胞疗法。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 Coya Therapeutics</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>基本面显示对最近的 Adobe 下调进行做空</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>AppLovin 股票动能增强，分析师目标价超过 800 美元</li>
<li>什么是空头头寸？如何使用它</li>
<li>人们希望哪些全国连锁店能在他们的州？ [2025 年调查]</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Coya Therapeutics 吗？</h2>
<p>在你考虑 Coya Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前... 而 Coya Therapeutics 并不在名单上。</p>
<p>虽然 Coya Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

COYA

<p>Coya Therapeutics, Inc.（纳斯达克代码：COYA）获得了五位分析师的一致 “买入” 评级，平均目标价为 16.20 美元。最近的评级包括 Lake Street Capital 的 16.00 美元目标，BTIG 的 15.00 美元，Chardan Capital 的 14.00 美元，以及 HC Wainwright 和 D. Boral Capital 的 18.00 美元目标。该股票目前交易价格为 5.72 美元，市值为 9558 万美元。Coya 在上个季度报告的每股亏损为 0.36 美元，未能达到预期。机构投资者持有该股票的 39.75%</p>

<p>Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned a consensus rating of &#34;Buy&#34; from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $16.20.</p>
<div class="lb-trans"><p>Coya Therapeutics, Inc.（纳斯达克代码：COYA - 获取免费报告）目前被五家评级公司一致评为 “买入”，MarketBeat Ratings 报告称。五位分析师对该股票给予了买入推荐。在过去一年中，更新了对该股票覆盖的经纪商的平均十二个月目标价为 16.20 美元。</p>
</div><p>Get <strong>Coya Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Coya Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Doing Your Holiday Shopping? These Stocks Might Make Great Gifts</li>
</ul>
<div class="lb-trans"><ul>
<li>你在做节日购物吗？这些股票可能是很好的礼物</li>
</ul>
</div><p>A number of brokerages recently weighed in on COYA. Lake Street Capital began coverage on shares of Coya Therapeutics in a research report on Wednesday, July 9th. They issued a &#34;buy&#34; rating and a $16.00 price target on the stock. BTIG Research restated a &#34;buy&#34; rating and set a $15.00 target price on shares of Coya Therapeutics in a report on Tuesday. Chardan Capital restated a &#34;buy&#34; rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday, September 17th. HC Wainwright restated a &#34;buy&#34; rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday, August 25th. Finally, D. Boral Capital restated a &#34;buy&#34; rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday.</p>
<div class="lb-trans"><p>一些经纪公司最近对 COYA 发表了看法。Lake Street Capital 于 7 月 9 日星期三在一份研究报告中开始覆盖 Coya Therapeutics 的股票。他们给予了 “买入” 评级，并设定了 16.00 美元的目标价。BTIG Research 在周二重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 15.00 美元。Chardan Capital 在 9 月 17 日星期三重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 14.00 美元。HC Wainwright 在 8 月 25 日星期一重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 18.00 美元。最后，D. Boral Capital 在周一重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 18.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on COYA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 COYA 的最新研究报告</strong></p>
</div><h2>Coya Therapeutics Stock Up 1.0%</h2>
<div class="lb-trans"><h2>Coya Therapeutics 股票上涨 1.0%</h2>
</div><ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><ul>
<li>这些生物技术公司针对多种神经退行性疾病</li>
</ul>
</div><p>NASDAQ:COYA traded up $0.06 during mid-day trading on Tuesday, reaching $5.72. 1,857 shares of the company were exchanged, compared to its average volume of 77,597. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $10.24. The company has a fifty day moving average of $6.13 and a 200 day moving average of $5.98. The stock has a market cap of $95.58 million, a PE ratio of -4.61 and a beta of 0.26.</p>
<div class="lb-trans"><p>在周二的午盘交易中，纳斯达克：COYA 上涨了 0.06 美元，达到了 5.72 美元。该公司交易了 1,857 股，相比其平均交易量 77,597 股。Coya Therapeutics 的 12 个月低点为 4.65 美元，12 个月高点为 10.24 美元。该公司的 50 日移动平均为 6.13 美元，200 日移动平均为 5.98 美元。该股票的市值为 9,558 万美元，市盈率为-4.61，贝塔值为 0.26。</p>
</div><p>Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.78 million. On average, equities research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Coya Therapeutics（纳斯达克代码：COYA - 获取免费报告）最近于 8 月 12 日星期二发布了其财报。该公司报告的每股收益（EPS）为-0.36 美元，低于市场共识预期的-0.22 美元，差距为-0.14 美元。该公司本季度的收入为 16 万美元，而市场共识预期为 78 万美元。平均而言，股票研究分析师预计 Coya Therapeutics 本财年的每股收益将为-1.15 美元。</p>
</div><h2>Hedge Funds Weigh In On Coya Therapeutics</h2>
<div class="lb-trans"><h2>对 Coya Therapeutics 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in COYA. Dauntless Investment Group LLC bought a new position in Coya Therapeutics during the first quarter worth $1,083,000. CM Management LLC boosted its position in shares of Coya Therapeutics by 25.0% in the first quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after acquiring an additional 40,000 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics in the second quarter valued at about $119,000. Jane Street Group LLC raised its stake in Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after purchasing an additional 13,176 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Coya Therapeutics in the first quarter valued at about $65,000. 39.75% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 COYA 的持仓进行了调整。Dauntless Investment Group LLC 在第一季度购买了 Coya Therapeutics 的新头寸，价值 1,083,000 美元。CM Management LLC 在第一季度将其在 Coya Therapeutics 的持仓增加了 25.0%。CM Management LLC 现在拥有该公司 200,000 股股票，价值 1,294,000 美元，此前在此期间又购买了 40,000 股。西北互助财富管理公司在第二季度收购了 Coya Therapeutics 的新头寸，价值约 119,000 美元。Jane Street Group LLC 在第一季度将其在 Coya Therapeutics 的股份提高了 101.7%。Jane Street Group LLC 现在拥有该公司 26,137 股股票，价值 169,000 美元，此前在上个季度又购买了 13,176 股。最后，Charles Schwab Investment Management Inc. 在第一季度收购了 Coya Therapeutics 的新头寸，价值约 65,000 美元。39.75% 的股票由机构投资者持有。</p>
</div><h2>Coya Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Coya Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.</p>
<div class="lb-trans"><p>Coya Therapeutics, Inc. 是一家临床阶段的生物技术公司，专注于开发专有药物产品，以调节调节性 T 细胞（Tregs）的功能。该公司的产品候选管道基于治疗性模式，如增强 Tregs 的生物制剂、Treg 衍生外泌体和自体 Treg 细胞疗法。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Coya Therapeutics</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Fundamentals Say Bet Against the Recent Adobe Downgrade</li>
<li>Canada Bond Market Holiday: How to Invest and Trade</li>
<li>AppLovin Stock Momentum Builds With $800+ Analyst Price Target</li>
<li>What is Short Interest? How to Use It</li>
<li>Which National Chains Do People Wish Were in Their State? [2025 Survey]</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Coya Therapeutics</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>基本面显示对最近的 Adobe 下调进行做空</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>AppLovin 股票动能增强，分析师目标价超过 800 美元</li>
<li>什么是空头头寸？如何使用它</li>
<li>人们希望哪些全国连锁店能在他们的州？ [2025 年调查]</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=COYA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coya Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Coya Therapeutics 吗？</h2>
</div><p>Before you consider Coya Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Coya Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前... 而 Coya Therapeutics 并不在名单上。</p>
</div><p>While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Coya Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Coya Therapeutics, Inc.（纳斯达克股票代码：COYA）获得分析师一致推荐为 “买入”